Morphic Therapeutic, a Massachusetts-based biotechnology company, has secured $80 million in Series B financing round.

The round was co-led by Omega Funds and Novo Holdings, with participation from new investors, including Invus and EcoR1 Capital.

The proceeds from the round will be used to fund the company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.

Previously, Morphic Therapeutic secured $51.5 million in its Series A funding round.